Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

Christine Greil, Monika Engelhardt, MD, Gabriele Ihorst, Hartmut Bertz, MD, Reinhard Marks, MD, Robert Zeiser, MD, Justus Duyster, MD, Jürgen Finke, MD, Ralph Wäsch, MD

Blood (2019) 134 (Supplement_1): 4597.

https://doi.org/10.1182/blood-2019-130146

Published: 2019

Journal Articles

High Throughput T Cell Receptor Sequencing Augments Diagnosis and Response Assessment in Patients with Angioimmunoblastic T Cell Lymphoma

Reinhard Marks, MD, Sylvia Kock, Claudia Wehr, Jürgen Finke, MD, Martin Werner, MD, Justus Duyster, Paul Fisch, MD

Blood (2017) 130 (Supplement 1): 1526.

https://doi.org/10.1182/blood.V130.Suppl_1.1526.1526

Published: 2017

Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Blood (2016) 128 (22): 2978.

https://doi.org/10.1182/blood.V128.22.2978.2978

Published: 2016

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Mathias Witzens-Harig, MD, Andreas Viardot, Ulrich Keller, Christian Buske, Anne Crombé, Elisabeth Hoenig, Johannes Atta, Johann Schmier, MD, Julia Meissner, MD, Anthony D. Ho, MD, Paul LaRosee, MD, Reinhard Marks, MD, Martin Dreyling, MD PhD, Georg Hess, MD

Blood (2016) 128 (22): 3028.

https://doi.org/10.1182/blood.V128.22.3028.3028

Published: 2016

Journal Articles

Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation

Sebastian Sommer, MD, Rainer Claus, MD, Hartmut Bertz, MD, Ralph Wäsch, MD, Reinhard Marks, MD, Robert Zeiser, MD, Ljudmila Bogatyrova, Jürgen Finke, MD, Michael Lübbert, MD

Blood (2016) 128 (22): 2247.

https://doi.org/10.1182/blood.V128.22.2247.2247

Published: 2016

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Georg Hess, MD, Andreas Hüttmann, MD, Reinhard Marks, MD, Mathias Witzens-Harig, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, Georg Lenz, MD, Christiane Pott, Annegret Kuhn, MD, Christian Ruckes, Matthias Theobald, MD, Ulrich Keller

Blood (2016) 128 (22): 5392.

https://doi.org/10.1182/blood.V128.22.5392.5392

Published: 2016

Journal Articles

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Ajib Salem, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Penter Livius, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, MD, Michael Lübbert, MD, Ralph Wäsch, MD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Omid Shah, MD, Robert S. Negrin, MD, Mats Brune, MD PhD, Alexandros Spyridonidis, MD PhD, Annette Schmitt-Graeff, MD, Walter J.F.M. van der Velden, MD PhD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MD PhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Jakob R. Passweg, Joerg Halter, MD, Gérard Socié, MD PhD, Dietrich W. Beelen, Prof. Dr. MD, Christian Peschel, MD, Andreas Neubauer, Jürgen Finke, Justus Duyster, MD, Nikolas von Bubnoff, MD

Blood (2016) 128 (22): 4561.

https://doi.org/10.1182/blood.V128.22.4561.4561

Published: 2016

Journal Articles

Low-Dose 5-Azacytidine Combined With Donor Lymphocyte Infusions (DLI), An Effective Outpatient Treatment Of AML/MDS Relapse After Allografting, Can Induce Long-Term Remissions: An Experience Of 72 Patients

Juliane Katharina Steinmann, Hartmut Bertz, MD, Ralph Wäsch, MD, Reinhard Marks, MD, Robert Zeiser, Lioudmila Bogatyreva, Michael Lübbert, MD, PhD, Jürgen Finke, MD

Blood (2013) 122 (21): 3317.

https://doi.org/10.1182/blood.V122.21.3317.3317

Published: 2013

Journal Articles

Conditioning with Fludarabine, BCNU, and Melphalan in Allogeneic Stem Cell Transplantation Results in Reduced Toxixcity and High Activity Against Advanced Hematologic Malignancies.

Reinhard Marks, MD, Karin Potthoff, MD, Joachim Hahn, MD, Gabriele Ihorst, Hartmut Bertz, MD, Alexandros Spyridonidis, MD, Ernst Holler, MD, Jurgen Finke, MD

Blood (2007) 110 (11): 3066.

https://doi.org/10.1182/blood.V110.11.3066.3066

Published: 2007

Journal Articles

Age-Stratified Treatment-Modalities for Patients with Primary CNS Lymphoma: Results of a Phase II Study and Two Pilot-Studies.

Gerald Illerhaus, MD, Reinhard Marks, MD, Fabian Mueller, Friedrich Feuerhake, MD, Christoph Ostertag, MD, Jurgen Finke, MD

Blood (2006) 108 (11): 4683.

https://doi.org/10.1182/blood.V108.11.4683.4683

Published: 2006

Journal Articles

Primary CNS Lymphoma - High-Dose-Chemotherapy with Autologous PBSCT and Hyperfractionated Radiotherapy as First-Line-Therapy - Results of a Multicenter Phase II Study.

Gerald Illerhaus, MD, Reinhard Marks, MD, Guenther Derigs, MD, Christan Peschel, MD, Norbert Frickhofen, MD, Roland Guttenberger, MD, Thomas Kubin, MD, Christoph B. Ostertag, MD, Juergen Finke, MD

Blood (2005) 106 (11): 680.

https://doi.org/10.1182/blood.V106.11.680.680

Published: 2005

NARROW

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

High Throughput T Cell Receptor Sequencing Augments Diagnosis and Response Assessment in Patients with Angioimmunoblastic T Cell Lymphoma

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Low-Dose 5-Azacytidine Combined With Donor Lymphocyte Infusions (DLI), An Effective Outpatient Treatment Of AML/MDS Relapse After Allografting, Can Induce Long-Term Remissions: An Experience Of 72 Patients

Conditioning with Fludarabine, BCNU, and Melphalan in Allogeneic Stem Cell Transplantation Results in Reduced Toxixcity and High Activity Against Advanced Hematologic Malignancies.

Age-Stratified Treatment-Modalities for Patients with Primary CNS Lymphoma: Results of a Phase II Study and Two Pilot-Studies.

Primary CNS Lymphoma - High-Dose-Chemotherapy with Autologous PBSCT and Hyperfractionated Radiotherapy as First-Line-Therapy - Results of a Multicenter Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only